___

• Aliustaoğlu, M. (2009). Temel kanser fizyopatolojisi. Klinik Gelişim, 22(3), 46-49.
• Amelina, C., Caruntu, I. D., Gıuşca, S. E., & Balan, R. A. (2010). Matrix metalloproteinases involvement in pathologic conditions. Romanian Journal of Morphology and Embryology, 51(2), 215–228.
• Apakkan Aksun, S., Bayındır, O., & Özmen, D. (2001). Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Türkiye Klinikleri Tıp Bilimleri, 21, 332–342.
• Aydın, O., Yıldız, L., Kefeli, M., Yüksel, C., Süllü, Y. (2006). Tiroid papiller karsinomlarda c-kit. Türk Patoloji Dergisi, 22(1), 17-20.
• Campo, E., Maria, J., Merino, J., Liotta, L., Neumann, R., & Stetler-Stevenson, W. G. (1992). Distribution of the 72-kDa type IV collagenase in non-neoplastic and neoplastic thyroid tissue. Human Pathology, 23, 1395–1401.
• Cho Mar, K., Eimoto, T., Tateyama, H., Arai, Y., Fujiyoshi Y., & Hamaguchi, M. (2006). Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology, 48, 286–294.
• Cvejic, D., Savin, S., Paunovic, I., Tatic, S., & Havelka, M. (2000) İmmunohistochemical localization of matrix metalloproteinase-2(MMP-2) in medullary thyroid carcinoma. Archive of Oncology, 8, 95-97.
• Franc, B. (2003). Observer variation of lesions of the thyroid. American Journal of Surgical Pathology, 27, 1177-1178.
• Hewitt, R., & Dan, K. (1996). Stromal cell expression of components of matrix degrading protease systems in human cancer. Enzyme Protein, 49,163–173.
• Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix Metalloproteinases: Regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/10.1016/j.cell.2010.03.015
• Koyun, E., Karadag, R., Ozkanli, S., Oguztuzun, S., Kocdogan, A. K., & Ozsoy, I. (2020) Caspase-3, p53 and Bcl-2 expression in basal cell carcinoma of the eyelid. Advances in Dermatology and Allergology, 37(4), 535–539.
• Liang, H., Zhong, Y., Luo, Z., Huang, Y., Lin, H., Luo, M., Zhan, S., Xie, K., Ma, Y., & Li, Q. Q. (2010). Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. International Journal of Biological Markers, 25, 38–45.
• Maeta, H,, Ohgi, S., & Terada, S. (2001). Protein expression of matrixmetalloproteinase 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroidcarcinomas. Virchows Archiv, 438, 121–128.
• Matrisian, L. M. (1990). Metalloproteinases and the inhibitors in matrixremodeling. Trends in Genetics, 6(4), 121–125.
• Mishunina, T. M., Kalinichenko, O. V., Tronko, M. D., & Statsenko, O. A. (2010). Caspase-3 activity in papillary thyroid carcinomas. Experimental Oncology, 32, 269-272.
• Natali, P. G., Berlingieri, M. T., Nicotra, M. R., Santoro, E., Bigotti, A., & Ullrich, A. (1995). Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Research, 55, 1787-1791.
• Saffar, H., Sanii, S., Emami, B., Heshmat, R., Panah, V. H , Azimi, S., & Tavangar, S. M. (2003). Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors. Pathology-Research and Practice, 209, 195-199.
• Sethi, C. S., Bailey, T. A., Luthert, P. J., & Chong, N. H. V. (2000) Matrix metalloproteinase biology applied to vitreoretinal disorders. British Journal of Ophthalmology, 84, 654–664.
• Tan, H., Ye, K., Wang, Z., & Tang, H. (2008). Clinicopathologic evaluation of immunohistochemical CD147 and MMP2 expression in differentiated thyroid carcinoma. Japanese Journal of Clinical Oncology, 338, 528–533.
• Tanaka, T., Umeki, K, Yamamoto, I., Kotani, T., Sakamoto, F., Noguchi, S., & Ohtaki, S. (1995). C-Kit proto-oncogene is more likely to lose expression in differentiated thyroid carcinoma than three thyroid-specific genes: thyroid peroxidase, thyroglobulin, and thyroid stimulating hormone receptor. Endocrine Journal, 42, 723-728.
• Tian, X., Cong, M., Zhou, W., Zhu, J., & Liu, Q. (2008). Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. Journal of International Medical Research, 36, 699–703.
• Tryggvason, K., Hoyhtya, M., & Ryke, C. (1993). Type IV collagenases in invasive tumors. Breast Cancer Research and Treatment, 24, 209–218.
• Zhang, H. Y., Meng, X., Du, Z. X., Fang, C. Q., Liu, G. L., Wang, H. Q., & Deng, W. W. (2009) Significance of survivin, caspase-3, and VEGF expression on thyroidcarcinoma. Clinical and Experimental Medicine, 9, 207–213.